Table 2. Cross-sectional associations of the MetS, components and number of components of the MetS with prevalent TAC.

	% prevalent TAC	Model 1*	Model 2†	Model 3‡
		PR (95% CI)	PR (95% CI)	PR (95% CI)
MetS and diabetes
Neither condition	24	1.00 (ref)	1.00 (ref)	1.00 (ref)
MetS	33	1.35 (1.24, 1.47)	1.21 (1.12, 1.30)	1.19 (1.11, 1.28)
Diabetes without MetS	38	1.57 (1.29, 1.91)	1.35 (1.14, 1.61)	1.33 (1.11, 1.58)
Diabetes with MetS	38	1.56 (1.40, 1.75)	1.35 (1.22, 1.50)	1.34 (1.21, 1.49)
Components of the MetS
Elevated BP	38	2.52 (2.29, 2.77)	1.52 (1.39, 1.67)	1.52 (1.39, 1.66)
Low HDL	29	1.07 (0.99, 1.16)	1.17 (1.10, 1.26)	1.17 (1.10, 1.26)
High triglycerides	30	1.11 (1.03, 1.22)	1.16 (1.08, 1.24)	1.14 (1.06, 1.22)
Impaired fasting glucose (≥ 100 mg/dl)	36	1.40 (1.30, 1.52)	1.21 (1.13, 1.30)	1.18 (1.10, 1.27)
Abdominal obesity	30	1.15 (1.06, 1.24)	1.11 (1.03, 1.20)	1.11 (1.03, 1.19)
Number of components of the MetS
0	12	1.00 (ref)	1.00 (ref)	1.00 (ref)
1	25	2.04 (1.69, 2.46)	1.49 (1.26, 1.76)	1.44 (1.22, 1.71)
2	31	2.51 (2.09, 3.02)	1.76 (1.49, 2.08)	1.70 (1.44, 2.01)
3	30	2.45 (2.03, 2.96)	1.75 (1.48, 2.08)	1.68 (1.42, 1.99)
4	37	3.01 (2.48, 3.64)	2.00 (1.68, 2.38)	1.94 (1.63, 2.31)
5	45	3.63 (2.92, 4.51)	2.17 (1.77, 2.65)	2.11 (1.72, 2.59)

^*Unadjusted.

^†Adjusted for age, gender and ethnicity.

^‡Adjusted for age, gender, ethnicity, LDL, smoking and lipid-lowering medications.

PR, prevalence ratio.